Dr. Asaad Trabolsi, MD

Dr. Trabolsi practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Trabolsi's NPI, 1447705678, was assigned on August 17, 2016. Dr. Trabolsi graduated from University of Aleppo Faculty of Medicine in 2014. Dr. Trabolsi holds Florida license ME133556.

Dr. Trabolsi's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Trabolsi's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Trabolsi is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Trabolsi to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Trabolsi practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Trabolsi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Trabolsi is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Trabolsi's licenses on file in 2 states: Florida and Pennsylvania.

CMS data shows 49 Medicare services from Dr. Trabolsi across 2 procedure codes in 2024, for 27 Medicare patients. Medicare paid $3,321 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 27 Medicare patients who saw Dr. Trabolsi in 2024. The largest group is 65 to 74, with 11 patients. 75% of them have high blood pressure, and 63% have high cholesterol. Their average risk score is 3.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Trabolsi's median patient age at 68, with 47% women.

In 2024, Dr. Trabolsi wrote 39 Medicare Part D claims for 13 patients. 87% of them were for generic drugs. They cover 4 drugs, with $255,667 in total drug cost. In 2021, CMS named 147 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Trabolsi for performance year 2024, reported as part of a group. Dr. Trabolsi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Trabolsi as offering telehealth.

Dmand AI links 12 papers to Dr. Trabolsi, published from 2017 to 2025. 2024 was the busiest year, with 4. The most frequent topics are Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols and Immunotherapy. Dr. Trabolsi has published most often in Blood Cancer J. Dr. Trabolsi's most frequent co-authors are Jonathan Harry Schatz, MD, Izidore Lossos, MD and Juan Pablo Alderuccio, MD.

CMS Open Payments shows 74 general payments to Dr. Trabolsi from 33 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 86% of the total. Daiichi Sankyo Inc. paid the most, $817.

Dr. Trabolsi graduated from University of Aleppo Faculty of Medicine in 2014.

Dr. Trabolsi is in network with 15 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.